158 related articles for article (PubMed ID: 32641652)
21. Calreticulin: a new horizon for the testing and treatment of myeloproliferative neoplasms.
Guglielmelli P; Bartalucci N; Rotunno G; Vannucchi AM
Expert Rev Hematol; 2014 Aug; 7(4):423-5. PubMed ID: 24849893
[TBL] [Abstract][Full Text] [Related]
22. Bilateral adrenal hemorrhage as a manifestation of extramedullary hematopoiesis in a patient with primary myelofibrosis.
Uminski K; Kumar R; Seftel M
Ann Hematol; 2018 Oct; 97(10):2011-2012. PubMed ID: 29713748
[No Abstract] [Full Text] [Related]
23. An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis.
Rozovski U; Verstovsek S; Manshouri T; Dembitz V; Bozinovic K; Newberry K; Zhang Y; Bove JE; Pierce S; Kantarjian H; Estrov Z
Haematologica; 2017 Jan; 102(1):79-84. PubMed ID: 27686378
[TBL] [Abstract][Full Text] [Related]
24. Increased mean platelet volume (MPV) is an independent predictor of inferior survival in patients with primary and secondary myelofibrosis.
Lucijanic M; Mitrovic Z; Cicic D; Prka Z; Pejsa V; Livun A; Stoos-Veic T; Romic Z; Zivkovic M; Lucijanic I; Fabris Z; Kusec R
Int J Hematol; 2018 Feb; 107(2):166-172. PubMed ID: 29022201
[TBL] [Abstract][Full Text] [Related]
25. Acquired delta-storage pool deficiency associated with idiopathic myelofibrosis.
Mouly S; Youssefian T; Souni F; Cramer E; Lefrere F; Varet B; Hermine O
Leuk Lymphoma; 2000 May; 37(5-6):623-7. PubMed ID: 11042524
[TBL] [Abstract][Full Text] [Related]
26. Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis.
Kourie HR; Ameye L; Paesmans M; Bron D
Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):264-8. PubMed ID: 26935576
[TBL] [Abstract][Full Text] [Related]
27. Myelofibrosis: a cause of increased transfusion requirement in a child with β-thalassemia intermedia.
Nirupam N; Maheshwari A; Rath B; Chandra J; Kumar P; Basu S; Nangia A
J Pediatr Hematol Oncol; 2012 Mar; 34(2):143-5. PubMed ID: 22009011
[TBL] [Abstract][Full Text] [Related]
28. NBEAL2 mutations and bleeding in patients with gray platelet syndrome.
Pluthero FG; Di Paola J; Carcao MD; Kahr WHA
Platelets; 2018 Sep; 29(6):632-635. PubMed ID: 29869935
[TBL] [Abstract][Full Text] [Related]
29. Myelofibrosis and acute megakaryoblastic leukemia in a child: topographic relationship between fibroblasts and megakaryocytes with an alpha-granule defect.
Breton-Gorius J; Bizet M; Reyes F; Dupuy E; Mear C; Vannier JP; Tron P
Leuk Res; 1982; 6(1):97-110. PubMed ID: 6461801
[TBL] [Abstract][Full Text] [Related]
30. Should any genetic defect affecting α-granules in platelets be classified as gray platelet syndrome?
Nurden AT; Nurden P
Am J Hematol; 2016 Jul; 91(7):714-8. PubMed ID: 26971401
[TBL] [Abstract][Full Text] [Related]
31. [Gray platelet syndrome, an example of myelofibrosis of megakaryocytic origin].
Caen JP; Cramer EM; Rendu F; Bryckaert M; Dupuy E; Levy-Toledano S
Bull Acad Natl Med; 1991 Oct; 175(7):1145-52; discussion 1152-3. PubMed ID: 1809489
[TBL] [Abstract][Full Text] [Related]
32. [Grey platelet disease].
Silvestre J; Batalha V; Martins A; Duque S; Freitas P; Dias AR; Campos L
Acta Med Port; 2009; 22(1):99-104. PubMed ID: 19341598
[TBL] [Abstract][Full Text] [Related]
33. Successful pregnancy and delivery in a woman with gray platelet syndrome.
Dolberg OJ; Ellis M
Isr Med Assoc J; 2011 Feb; 13(2):117-8. PubMed ID: 21443042
[No Abstract] [Full Text] [Related]
34. The underappreciated risk of thrombosis and bleeding in patients with myelofibrosis: a review.
Kc D; Falchi L; Verstovsek S
Ann Hematol; 2017 Oct; 96(10):1595-1604. PubMed ID: 28808761
[TBL] [Abstract][Full Text] [Related]
35. [Diagnosis and treatment of BCR/ABL-negative myeloproliferative diseases--principles and rationale of CZEMP recommendations].
Schwarz J; Penka M; Campr V; Pospísilová D; Kren L; Nováková L; Bodzásová C; Brychtová Y; Cerná O; Dulícek P; Joniásová A; Kissová J; Korístek Z; Schützová M; Vonke I; Walterová L
Vnitr Lek; 2011 Feb; 57(2):189-213. PubMed ID: 21416861
[TBL] [Abstract][Full Text] [Related]
36. Gray platelet syndrome.
Bain BJ; Bhavnani M
Am J Hematol; 2011 Dec; 86(12):1027. PubMed ID: 21800352
[No Abstract] [Full Text] [Related]
37. Primary myelofibrosis and the myeloproliferative neoplasms: the role of individual variation.
Stein BL; Moliterno AR
JAMA; 2010 Jun; 303(24):2513-8. PubMed ID: 20571018
[TBL] [Abstract][Full Text] [Related]
38. Template bleeding time and clinical hemorrhage in myeloproliferative disease.
Murphy S; Davis JL; Walsh PN; Gardner FH
Arch Intern Med; 1978 Aug; 138(8):1251-3. PubMed ID: 277084
[TBL] [Abstract][Full Text] [Related]
39. Pathogen-reduced platelets for the prevention of bleeding.
Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
[TBL] [Abstract][Full Text] [Related]
40. Case report of Grey Platelet Syndrome in pregnancy.
Agarwal N; Willmott FJ; Bowles L; Pasi KJ; Beski S
Haemophilia; 2011 Sep; 17(5):825-6. PubMed ID: 21492324
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
